178 related articles for article (PubMed ID: 35091554)
1. Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients.
Grimm J; Simnica D; Jäkel N; Paschold L; Willscher E; Schulze S; Dierks C; Al-Ali HK; Binder M
Blood Cancer J; 2022 Jan; 12(1):19. PubMed ID: 35091554
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
Pepe S; Scalzulli E; Colafigli G; Di Prima A; Diverio D; Mancini M; Latagliata R; Martelli M; Foà R; Breccia M
Ann Hematol; 2020 Oct; 99(10):2405-2416. PubMed ID: 32813071
[TBL] [Abstract][Full Text] [Related]
3. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
Pleyer L; Döhner H; Dombret H; Seymour JF; Schuh AC; Beach CL; Swern AS; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212292
[TBL] [Abstract][Full Text] [Related]
4. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.
Pleyer L; Burgstaller S; Girschikofsky M; Linkesch W; Stauder R; Pfeilstocker M; Schreder M; Tinchon C; Sliwa T; Lang A; Sperr WR; Krippl P; Geissler D; Voskova D; Schlick K; Thaler J; Machherndl-Spandl S; Theiler G; Eckmüllner O; Greil R
Ann Hematol; 2014 Nov; 93(11):1825-38. PubMed ID: 24951123
[TBL] [Abstract][Full Text] [Related]
5. Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
Cabezón M; Malinverni R; Bargay J; Xicoy B; Marcé S; Garrido A; Tormo M; Arenillas L; Coll R; Borras J; Jiménez MJ; Hoyos M; Valcárcel D; Escoda L; Vall-Llovera F; Garcia A; Font LL; Rámila E; Buschbeck M; Zamora L;
Clin Epigenetics; 2021 Jan; 13(1):9. PubMed ID: 33446256
[TBL] [Abstract][Full Text] [Related]
6. The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study.
Tombak A; Uçar MA; Akdeniz A; Tiftik EN; Gören Şahin D; Akay OM; Yıldırım M; Nevruz O; Kis C; Gürkan E; Solmaz ŞM; Özcan MA; Yıldırım R; Berber İ; Erkurt MA; Fıratlı Tuğlular T; Tarkun P; Yavaşoğlu İ; Doğu MH; Sarı İ; Merter M; Özcan M; Yıldızhan E; Kaynar L; Mehtap Ö; Uysal A; Şahin F; Salim O; Sungur MA
Turk J Haematol; 2016 Dec; 33(4):273-280. PubMed ID: 27095141
[TBL] [Abstract][Full Text] [Related]
7. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
[TBL] [Abstract][Full Text] [Related]
8. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
[TBL] [Abstract][Full Text] [Related]
9. Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.
Menezes DL; See WL; Risueño A; Tsai KT; Lee JK; Ma J; Khan R; Prebet T; Skikne B; Beach CL; Thakurta A; Gandhi A
Br J Haematol; 2023 Jun; 201(6):1129-1143. PubMed ID: 36990798
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Azacitidine in De Novo and Relapsed Acute Myeloid Leukemia: A Retrospective Comparative Study.
Gemuenden C; Benz R; Senn O; Goede JS; Manz MG; Gerber B
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):811-5. PubMed ID: 26437871
[TBL] [Abstract][Full Text] [Related]
11. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).
Goodyear OC; Dennis M; Jilani NY; Loke J; Siddique S; Ryan G; Nunnick J; Khanum R; Raghavan M; Cook M; Snowden JA; Griffiths M; Russell N; Yin J; Crawley C; Cook G; Vyas P; Moss P; Malladi R; Craddock CF
Blood; 2012 Apr; 119(14):3361-9. PubMed ID: 22234690
[TBL] [Abstract][Full Text] [Related]
12. Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
Fozza C; Corda G; Barraqueddu F; Virdis P; Contini S; Galleu A; Isoni A; Dore F; Angelucci E; Longinotti M
Leuk Res; 2015 Sep; 39(9):957-63. PubMed ID: 26209197
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.
Craddock C; Jilani N; Siddique S; Yap C; Khan J; Nagra S; Ward J; Ferguson P; Hazlewood P; Buka R; Vyas P; Goodyear O; Tholouli E; Crawley C; Russell N; Byrne J; Malladi R; Snowden J; Dennis M
Biol Blood Marrow Transplant; 2016 Feb; 22(2):385-390. PubMed ID: 26363443
[TBL] [Abstract][Full Text] [Related]
14. Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts.
Kadia TM; Thomas XG; Dmoszynska A; Wierzbowska A; Minden M; Arthur C; Delaunay J; Ravandi F; Kantarjian H
Am J Hematol; 2015 Jul; 90(7):E139-41. PubMed ID: 25858582
[No Abstract] [Full Text] [Related]
15. Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
Maurillo L; Buccisano F; Spagnoli A; Voso MT; Fianchi L; Papayannidis C; Gaidano GL; Breccia M; Musto P; De Bellis E; Del Principe MI; Lunghi M; Lessi F; Martinelli G; Venditti A
Ann Hematol; 2018 Oct; 97(10):1767-1774. PubMed ID: 29947973
[TBL] [Abstract][Full Text] [Related]
16. Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
Müller-Tidow C; Tschanter P; Röllig C; Thiede C; Koschmieder A; Stelljes M; Koschmieder S; Dugas M; Gerss J; Butterfaß-Bahloul T; Wagner R; Eveslage M; Thiem U; Krause SW; Kaiser U; Kunzmann V; Steffen B; Noppeney R; Herr W; Baldus CD; Schmitz N; Götze K; Reichle A; Kaufmann M; Neubauer A; Schäfer-Eckart K; Hänel M; Peceny R; Frickhofen N; Kiehl M; Giagounidis A; Görner M; Repp R; Link H; Kiani A; Naumann R; Brümmendorf TH; Serve H; Ehninger G; Berdel WE; Krug U;
Leukemia; 2016 Mar; 30(3):555-61. PubMed ID: 26522083
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance).
Vij R; Le-Rademacher J; Laumann K; Hars V; Owzar K; Shore T; Vasu S; Cashen A; Isola L; Shea T; DeMagalhaes-Silverman M; Hurd D; Meehan K; Beardell F; Devine S
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1984-1992. PubMed ID: 31212080
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
[TBL] [Abstract][Full Text] [Related]
19. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
Lübbert M; Ihorst G; Sander PN; Bogatyreva L; Becker H; Wijermans PW; Suciu S; Bissé E; Claus R
Br J Haematol; 2017 Feb; 176(4):609-617. PubMed ID: 27905102
[TBL] [Abstract][Full Text] [Related]
20. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
